Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective studySi Houn Hahn, Priya S. Kishnani, David W. Stockton et al.|Genetics in Medicine|2018Cited by 31
Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe diseasePriya S. Kishnani, Si Houn Hahn, James B. Gibson et al.|Genetics in Medicine|2019Cited by 16
Clinical characteristics and genotypes in the ADVANCE baseline dataset, a comprehensive cohort of us children and youth with Pompe diseasePriya S. Kishnani, Sihoun Hahn, Michael J. Gambello et al.|Molecular Genetics and Metabolism|2016Cited by 1
52-week efficacy and safety profile of alglucosidase alfa produced at 4000 liter scale in US patients with Pompe disease: ADVANCE, a phase 4 open-label prospective studySihoun Hahn, Priya S. Kishnani, Loren Peña et al.|Molecular Genetics and Metabolism|2016Cited by 0